Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 4/20 | 0.64 |
| ▸ | ITGA2B | P08514 | 3/20 | 0.64 |
| ▸ | GPR132 | Q9UNW8 | 2/20 | 0.61 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.59 |
| ▸ | ITGAV | P06756 | 1/20 | 0.59 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.54 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27871439 | 0.93 | ITGB3 (0.73) | ITGB3ITGA2BGPR132ITGB1ITGAV | |
| SCHEMBL1123264 | 0.91 | GPR132 (0.68) | ITGB3ITGA2BGPR132ITGB1ITGAV | |
| SCHEMBL6029880 | 0.88 | GPR132 (0.73) | ITGB3ITGA2BGPR132GAARAB9A | |
| SCHEMBL1123243 | 0.87 | GPR132 (0.72) | ITGB3ITGA2BGPR132GAARAB9A | |
| SCHEMBL5927205 | 0.87 | GPR132 (0.72) | ITGB3ITGA2BGPR132GAARAB9A | |
| SCHEMBL1122833 | 0.87 | GPR132 (0.72) | ITGB3ITGA2BGPR132GAARAB9A | |
| SCHEMBL5921820 | 0.86 | GPR132 (0.61) | ITGB3ITGA2BGPR132ITGB1ITGAV | |
| SCHEMBL5921824 | 0.86 | GPR132 (0.61) | ITGB3ITGA2BGPR132ITGB1ITGAV | |
| SCHEMBL2632872 | 0.86 | PTPN1 (0.74) | ITGB1PTPN1CA2CA1CTSB | |
| SCHEMBL8196220 | 0.86 | PTPN1 (0.74) | ITGB1PTPN1CA2CA1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060247260-A1 | Bis (hetero) aryl carboxamide derivatives for use as PG12 antagonists | BAYER HEALTHCARE AG (DE) | 2006-11-02 | — | — | US | claimed |
| EP-1594846-A1 | BIS(HETERO)ARYL CARBOXAMIDE DERIVATIVES FOR USE AS PGI2 ANTAGONISTS | Bayer HealthCare AG (DE) | 2005-11-16 | — | — | EP | claimed |
| WO-2004069805-A1 | BIS(HETERO)ARYL CARBOXAMIDE DERIVATIVES FOR USE AS PGI2 ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2004-08-19 | — | — | WO | claimed |
| US-20060247260-A1 | Bis (hetero) aryl carboxamide derivatives for use as PG12 antagonists | BAYER HEALTHCARE AG (DE) | 2006-11-02 | — | — | US | disclosed |
| EP-1594846-A1 | BIS(HETERO)ARYL CARBOXAMIDE DERIVATIVES FOR USE AS PGI2 ANTAGONISTS | Bayer HealthCare AG (DE) | 2005-11-16 | — | — | EP | disclosed |
| WO-2004069805-A1 | BIS(HETERO)ARYL CARBOXAMIDE DERIVATIVES FOR USE AS PGI2 ANTAGONISTS | BAYER HEALTHCARE AG (DE) | 2004-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247260-A1 | Bis (hetero) aryl carboxamide derivatives for use as PG12 antagonists | HRH2, BPHL, HRH1 | ITGB3 872/4885ITGA2B 524/4885GPR132 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.